| Grade of Recommendation |
Clarity of risk/benefit |
Quality of supporting evidence |
Implications |
|
1A.
Strong recommendation. High quality evidence
|
Benefits clearly outweigh risk and burdens, or vice
versa
|
Consistent evidence from well performed randomized,
controlled trials or overwhelming evidence of some other form. Further research is unlikely to change our
confidence in the estimate of benefit and risk.
|
Strong recommendation, can apply to most patients in
most circumstances without reservation
|
|
1B.
Strong recommendation. Moderate quality evidence
|
Benefits clearly outweigh risk and burdens, or vice
versa
|
Evidence from randomized, controlled trials with
important limitations (inconsistent results, methodologic
flaws, indirect or imprecise), or very strong evidence of some other
form. Further research (if performed) is likely to have an impact on
our confidence in the estimate of benefit and
risk and may change the estimate.
|
Strong recommendation, likely to apply to most
patients
|
1C.
Strong recommendation. Low quality evidence
|
Benefits appear to outweigh risk and burdens, or
vice versa
|
Evidence from observational studies, unsystematic
clinical experience, or from randomized, controlled trials with serious
flaws. Any estimate of effect is uncertain.
|
Relatively strong recommendation; might change when
higher quality evidence becomes available
|
2A.
Weak recommendation. High quality evidence
|
Benefits closely balanced with risks and burdens
|
Consistent evidence from well performed randomized,
controlled trials or overwhelming evidence of some other form.
Further research is unlikely to change our
confidence in the estimate of benefit and risk.
|
Weak recommendation, best action may differ
depending on circumstances or patients or societal values
|
|
2B.
Weak recommendation. Moderate quality evidence
|
Benefits closely balanced with risks and burdens,
some uncertainly in the estimates of benefits, risks and burdens
|
Evidence from randomized, controlled trials with
important limitations (inconsistent results, methodologic
flaws, indirect or imprecise), or very strong evidence of some other form.
Further research (if performed) is likely to have an impact on our confidence
in the estimate of benefit and risk and may change the estimate.
|
Weak recommendation, alternative approaches likely
to be better for some patients under some circumstances
|
|
2C.
Weak recommendation. Low quality evidence
|
Uncertainty in the estimates of benefits, risks, and
burdens; benefits may be closely balanced with risks and burdens
|
Evidence from observational studies, unsystematic
clinical experience, or from randomized, controlled trials with serious
flaws. Any estimate of effect is uncertain.
|
Very weak recommendation; other alternatives may be
equally reasonable.
|